Top 10 Companies in the Global Acid Maltase Market (2026): Market Leaders Powering Global Acid Maltase

MARKET INSIGHTS

Global Acid Maltase market size was valued at USD 325.7 million in 2024. The market is projected to grow from USD 354.2 million in 2025 to USD 612.8 million by 2032, exhibiting a CAGR of 8.1% during the forecast period.

Acid Maltase (also known as alpha‑glucosidase) is a lysosomal enzyme that plays a critical role in glycogen metabolism. This enzyme breaks down glycogen into glucose molecules, primarily in muscle cells. Deficiency of this enzyme leads to Pompe disease, a rare genetic disorder. The enzyme finds applications in both pharmaceutical formulations and as a food additive for starch processing.

The market growth is driven by increasing prevalence of glycogen storage disorders, particularly Pompe disease which affects approximately 1 in 40,000 births globally. Rising healthcare expenditure in emerging economies and advancements in enzyme replacement therapies are creating new opportunities. Major players like Genzyme (Sanofi) have recently expanded their production capacities for Myozyme (alglucosidase alfa), the only FDA‑approved treatment for Pompe disease, indicating strong market potential. Pharmaceutical applications currently dominate the market share, though food‑grade acid maltase is gaining traction in specialty food processing applications.

Global Acid Maltase Market – View in Detailed Research Report

Top 10 Companies in the Global Acid Maltase Market

1. Sanofi Genzyme

   Headquarters: Paris, France / New York, USA

   Key Offering: alglucosidase alfa (Myozyme/Lumizyme) – the first FDA‑approved enzyme replacement therapy for Pompe disease.

   Sanofi Genzyme has invested heavily in bioprocessing capabilities, expanding its manufacturing footprint to meet rising demand in North America and Europe. The company’s focus on glycoengineering ensures optimal mannose‑6‑phosphate content, which improves lysosomal targeting and clinical outcomes.

   Growth Initiatives:

   • Expansion of contract manufacturing agreements in Asia‑Pacific to capture emerging markets.
   • Investment in next‑generation formulations (Nexviazyme) with enhanced uptake and reduced infusion frequency.
   • Strategic partnership with patient advocacy groups to streamline access programs in low‑ and middle‑income regions.

2. Amicus Therapeutics

   Headquarters: West Lafayette, USA

   Key Offering: cipaglucosidase alfa (Pombiliti) – a next‑generation enzyme replacement therapy approved in 2023, featuring improved pharmacokinetics and reduced immunogenicity.

   Amicus has leveraged its partnership with Opko Health to accelerate clinical development and market launch, positioning itself as a credible challenger to established players.

   Growth Initiatives:

   • Expansion of global sales force targeting emerging markets with high unmet need.
   • Investment in real‑world evidence studies to support value‑based reimbursement models.
   • Collaboration with biotech firms to explore gene‑editing approaches for long‑term disease control.

3. Novozymes A/S

   Headquarters: Lyngby, Denmark

   Key Offering: recombinant acid maltase for industrial starch processing – high‑activity, cost‑effective enzyme suitable for food‑grade applications.

   Novozymes’ strong R&D pipeline in enzyme stability and substrate specificity has positioned it as a leader in the food‑grade segment.

   Growth Initiatives:

   • Development of plant‑based enzyme variants to meet clean‑label demand.
   • Expansion of distribution network across Southeast Asia and Latin America.
   • Investment in digital process analytics to reduce batch variability.

4. DSM‑Firmenich

   Headquarters: Heerlen, Netherlands / Basel, Switzerland

   Key Offering: specialty acid maltase blends for bakery and beverage applications, featuring proprietary stabilisers that extend shelf life.

   DSM‑Firmenich combines expertise in food science and biotechnology to deliver high‑performance enzymes to the global food market.

   Growth Initiatives:

   • Launch of a new line of low‑sugar baking enzymes targeting health‑conscious consumers.
   • Strategic alliances with major bakery chains to pilot pilot‑scale production.
   • Investment in sustainability metrics, including carbon‑neutral manufacturing.

5. Neogen Corporation (Megazyme)

   Headquarters: Columbia, Maryland, USA

   Key Offering: high‑purity acid maltase for laboratory and small‑scale industrial use, supporting diagnostic and research applications.

   Neogen’s focus on analytical quality ensures reliable performance for research institutions and biotech startups.

   Growth Initiatives:

   • Expansion of analytical services to support regulatory submissions for novel enzyme therapeutics.
   • Collaboration with academic partners to validate new diagnostic assays.
   • Investment in scalable micro‑fermentation platforms for rapid prototype production.

6. Creative Enzymes

   Headquarters: San Diego, USA

   Key Offering: recombinant acid maltase for specialty food applications, including low‑fat dairy and plant‑based protein products.

   Creative Enzymes positions itself as a niche supplier delivering customized enzyme solutions for emerging food categories.

   Growth Initiatives:

   • Development of enzyme blends for vegan cheese production.
   • Expansion of e‑commerce platform to reach boutique food manufacturers.
   • Investment in green chemistry to reduce solvent use in enzyme purification.

7. Spark Therapeutics (Roche)

   Headquarters: New York, USA / Basel, Switzerland

   Key Offering: early‑stage AAV‑based gene therapy targeting GAA deficiency, aimed at delivering a single, long‑lasting correction.

   Spark’s pipeline is supported by Roche’s extensive gene‑therapy platform and regulatory experience.

   Growth Initiatives:

   • Clinical trial acceleration through adaptive trial designs.
   • Strategic partnership with regulatory agencies to streamline approval pathways.
   • Investment in manufacturing scale‑up for clinical and commercial supply.

8. Passage Bio

   Headquarters: San Diego, USA

   Key Offering: AAV‑mediated gene delivery system for Pompe disease, with a focus on optimizing viral capsid design.

   Passage Bio’s technology is tailored to enhance tissue‑specific delivery and reduce off‑target effects.

   Growth Initiatives:

   • Expansion of pre‑clinical studies across multiple animal models.
   • Collaboration with biotech firms to refine vector manufacturing.
   • Investment in computational modelling to predict biodistribution.

9. Maze Therapeutics

   Headquarters: San Diego, USA

   Key Offering: small‑molecule substrate‑reduction therapy for Pompe disease, targeting glycogen synthesis pathways.

   Maze’s approach offers a non‑invasive alternative to enzyme replacement.

   Growth Initiatives:

   • Early‑stage clinical trials to establish safety profile.
   • Partnerships with academic centers to explore combination therapies.
   • Investment in formulation science to improve oral bioavailability.

10. Proenzyme Inc.

    Headquarters: Westbury, New York, USA

    Key Offering: high‑purity acid maltase for diagnostic kits and research reagents.

    Proenzyme’s focus on analytical reliability supports diagnostics for lysosomal storage disorders.

    Growth Initiatives:

    • Expansion of diagnostic assay portfolio to include multiplex panels.
    • Strategic alliances with clinical laboratories for broader distribution.
    • Investment in automation of purification processes to reduce cost per unit.

Download FREE Sample Report: Global Acid Maltase Market – View in Detailed Research Report

Get Full Report: Global Acid Maltase Market – View in Detailed Research Report

Outlook and Future Trends

In the next decade, the acid maltase market will experience a shift from enzyme replacement to gene‑based solutions. The first AAV‑mediated therapy candidates are poised to reach regulatory approval, potentially reducing the burden of biweekly infusions. Concurrently, substrate‑reduction drugs will carve out a niche for patients who are refractory to ERT, offering a non‑invasive treatment path.

Market participants will need to navigate complex reimbursement frameworks while addressing the high cost of biologics. Companies that embed real‑world evidence into their value propositions, and that partner with payers to demonstrate long‑term cost‑effectiveness, will secure a competitive edge.

On the food side, consumer demand for clean‑label, enzyme‑based ingredients will drive growth in specialty bakery and beverage sectors. Innovations in enzyme stabilisation and plant‑based production will enable lower‑cost, high‑performance products that satisfy both regulatory and consumer expectations.

Overall, the convergence of advanced manufacturing, gene‑therapy research, and a growing emphasis on value‑based pricing will shape the trajectory of the global acid maltase market through 2034.